SCHEDULE: Rosalind Entities Disclose 7.46% Stake in Fennec Pharma

Rosalind Advisors, Rosalind Master Fund, Steven Salamon, and Gilad Aharon have jointly disclosed a 7.46% beneficial ownership stake in Fennec Pharmaceuticals Inc.

Summary

• Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven A. J. Salamon, and Gil Aharon collectively reported beneficial ownership of 2,076,840 common shares of Fennec Pharmaceuticals Inc.
• This aggregate amount represents 7.46% of Fennec Pharmaceuticals Inc.'s common shares outstanding.
• The percentage is based on 27,831,698 ordinary shares outstanding as of August 11, 2025, as reported in the company's 10Q filing of August 14, 2025.
• All reporting persons share both voting power and dispositive power over the 2,076,840 shares.
• Rosalind Advisors Inc. is the investment advisor to Rosalind Master Fund L.P., and Steven Salamon and Gilad Aharon are portfolio managers and members of Rosalind Advisors Inc.
• Rosalind Advisors Inc. and Steven Salamon disclaim beneficial ownership of the shares, despite being deemed beneficial owners due to their roles.

Sentiment

Score: 7

Explanation: The disclosure of a significant beneficial ownership stake by institutional investors and their principals indicates a notable investment in Fennec Pharmaceuticals Inc., which can be perceived as a vote of confidence.

Positives

• The disclosure of a significant beneficial ownership stake by institutional investors and their principals can be interpreted as a vote of confidence in Fennec Pharmaceuticals Inc.

Risks

• A significant beneficial ownership stake by a group of investors could potentially lead to increased shareholder activism or influence over corporate decisions.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the acquisition of a significant stake by institutional investors as a positive signal, potentially increasing investor confidence and demand for the company's shares.

Key Dates

Recommendation

The filing indicates a substantial beneficial ownership stake by Rosalind Advisors and its associated entities in Fennec Pharmaceuticals. While this signals institutional confidence, a Schedule 13G filing primarily discloses ownership and does not provide comprehensive financial or operational details to warrant a 'buy' or 'sell' recommendation. A 'hold' position is prudent, pending further fundamental analysis of the company's performance and strategic direction.

Keywords

Fennec Pharmaceuticals, Rosalind Advisors, Rosalind Master Fund, Beneficial Ownership, Schedule 13G, Institutional Investment, Common Shares, Equity Stake